UCB, a global biopharmaceutical company, announced the detailed results of the head-to-head phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results